What is MeMed?
MeMed operates at the intersection of immunology and data science, specializing in the translation of complex immune system signals into actionable clinical insights. The company's core competency lies in host-response profiling, a methodology that analyzes the body's physiological reaction to disease rather than relying solely on pathogen detection. By integrating advanced machine-learning algorithms, MeMed is effectively redefining the standard of care for infectious diseases and inflammatory conditions. Its market position is characterized by a focus on high-impact diagnostic solutions that provide clinicians with the clarity needed to make informed treatment decisions, thereby reducing unnecessary antibiotic usage and improving patient outcomes across global healthcare systems.
How much funding has MeMed raised?
MeMed has raised a total of $93M across 1 funding round:
Private Equity
$93M
Private Equity (2022): $93M with participation from Horizons Ventures, Shavit Capital, La Maison Partners, and Social Capital
Key Investors in MeMed
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future. The company seeks to support innovative projects that have the potential to create transformative changes.
Shavit Capital
Shavit Capital is an investment practice specializing in late-stage investments in Israeli and Israeli-related companies, focusing on firms with proven technologies and strong management teams.
La Maison Partners
La Maison Partners is a human-sized investment firm driven by entrepreneurs, focusing on venture capital, growth, and LBO strategies to build future industry champions.
What's next for MeMed?
With this major enterprise-level funding, MeMed is positioned to accelerate its commercialization strategy and deepen its penetration into international markets. The strategic roadmap likely involves the expansion of its clinical validation studies and the integration of its diagnostic platform into existing hospital workflows. By focusing on the scalability of its machine-learning infrastructure, the company aims to solidify its leadership in the precision medicine sector. Future growth will be driven by the continued adoption of its diagnostic tests, which are increasingly viewed as essential tools for modern clinical decision support systems. The firm remains committed to its mission of transforming disease management through data-driven insights, ensuring that its technological advancements translate into tangible improvements in patient care and healthcare efficiency.
See full MeMed company page
